Receipt of live, attenuated vaccine within  days prior to the first dose of investigational treatment; Note: patients, if enrolled, should not receive live vaccine during the study and up to  days after the last dose of investigational treatment
Receipt of a live vaccine within  days prior to registration for protocol therapy
Receipt of a live, attenuated vaccine within  weeks prior to randomization, during treatment, or within  months following the last dose of atezolizumab/placebo
Receipt of live vaccine within  days of planned first dose of TVEC
Receipt of a live virus vaccine within  days prior to Day  of Cycle 
Receipt of a live vaccine within  days of start of study treatment
Receipt of a live virus vaccine within  days prior to Day  of Cycle 
Receipt of live attenuated vaccine within  days prior to the first dose of study drug. Note: Patients, if enrolled, should not receive live vaccine whilst receiving study treatment and up to  days after the last dose of study treatment.
Receipt of live attenuated vaccine within  days prior to the first dose of IP. Note: Subjects, if enrolled, should not receive live vaccine whilst receiving IP and up to  days after the last dose of IP.
Receipt of attenuated vaccine within  weeks prior to starting study treatment.
Receipt of a live vaccine =<  days prior to registration
Receipt of live attenuated vaccine within  days before the first dose of study treatment
Receipt of live attenuated vaccination within  days prior to the first dose of IP; Note: Patients, if enrolled, should not receive live vaccine during the study and up to  days after the last dose of IP
Receipt of live attenuated vaccine within  calendar days prior to the first study treatment is NOT permitted
Receipt of live attenuated vaccination within  days prior the first dose of durvalumab (NOTE: If a vaccine is part of the treatment regimen for the indication under study, the vaccine is permitted)
Receipt of live attenuated vaccine within  days prior to study entry; enrolled patients should not receive live vaccine during the study and  days after the last dose of durvalumab
Receipt of a live vaccine within  days of receipt of study therapy
Receipt of a live virus vaccine =<  months prior to registration
Receipt of live attenuated vaccination within  days prior to study entry or within  days of receiving durvalumab (e.g. live attenuated influenza vaccine [LAIV], measles/mumps/rubella vaccine [MMR], variola virus vaccine [VAR], zoster, yellow fever, etc.)
Receipt of live, attenuated vaccine within  days prior to the first dose of investigational products (NOTE: Subjects, if enrolled, should not receive live vaccine during the study and  days after the last dose of investigational products)
Receipt of live, attenuated vaccine within  days prior to the first dose of durvalumab and tremelimumab (NOTE: subjects, if enrolled, should not receive live vaccine during the study and for  days after the last dose of both drugs)
Receipt of a live/attenuated vaccine within  weeks prior to the screening visit.
Receipt of a live vaccine within  days of study entry
Receipt of live, attenuated vaccine within  days prior to the first dose of durvalumab (Note: enrolled patients should not receive live vaccine during the study and for  days after the last dose of durvalumab)
Receipt of a live, attenuated vaccine within  days prior to the first dose of MEDI and tremelimumab (NOTE: subjects, if enrolled, should not receive live vaccine during the study or for  days after the last dose of both drugs)
Receipt of live attenuated vaccine within  days prior to the first dose of IP. Note: Patients, if enrolled, should not receive live vaccine during the study and up to  days after the last dose of IP.
Receipt of live or live attenuated vaccine within  weeks prior to enrollment
Receipt of live vaccine within  days prior to the first dose of trial treatment
Receipt of any live vaccine within  weeks.
Receipt of live attenuated vaccine within  days prior to the first dose of investigational treatment; Note: patients, if enrolled, should not receive live vaccine during the study and up to  days after the last dose of investigational treatment
Receipt of live attenuated vaccine within  days prior to the first dose of study drugs; Note: Patients, if enrolled, should not receive live vaccine whilst receiving treatment with study drugs and up to  days after the last dose of study drugs
Receipt of live, attenuated vaccine within  days prior to study entry or the first dose of MEDI.\r\n* Note: patients, if enrolled, should not receive live vaccine during the study and up to  days after the last dose of IP.
Receipt of live, attenuated vaccine within  days prior to the first dose of durvalumab
Receipt of live, attenuated vaccine within  days prior to the first dose of investigational product
Receipt of live, attenuated vaccine within  days prior to the first dose of IP (NOTE: Subjects, if enrolled, should not receive live vaccine during the study and for  days after the last dose of durvalumab).
Receipt of a live vaccine within  days before the first dose of study treatment.
Any non-oncology live or attenuated vaccine therapy used for prevention of infectious diseases within  days prior to the first dose of tremelimumab; if patients is enrolled, patient should not receive live vaccine during the study and  days after the last dose of tremelimumab
Receipt of a live vaccine within  weeks prior to rituximab administration
Receipt of a live attenuated vaccine within  weeks prior to study drug
Receipt of live attenuated vaccine within  days prior to the first dose of IP
Receipt of live, attenuated vaccine within  days prior to the first dose of MEDI
Receipt of live, attenuated vaccine within  days prior to the first dose of Investigational Product;
Receipt of live, attenuated vaccine within  days prior to the first dose of investigational products )
Receipt of live, attenuated vaccine within  days prior to the first dose of MEDI
Receipt of a live vaccine within  days of receipt of study therapy
Receipt of a live (attenuated) vaccine within  month prior to Screening
Receipt of a live virus vaccine within  days prior to Day  of Cycle 
Receipt of a live vaccine within  days of receipt of study therapy
No receipt of a live vaccine within  weeks prior to registration
Receipt of live vaccine within  weeks prior to study drug administration
Receipt of live attenuated vaccination within  days prior to study entry or within  days of receiving durvalumab; for example, the intramuscular influenza vaccine can be administered but the intranasal vaccine is a live attenuated virus that cannot be given
Receipt of any live vaccine within  weeks prior to first dose of study treatment.
Receipt of live (including attenuated) vaccines during the study, or anticipation of need for such a vaccine during the study.
Receipt of live attenuated vaccination within  days prior to the first vaccine
